HydRA: Deep-learning models for predicting RNA-binding capacity from protein interaction association context and protein sequence

RNA-binding proteins (RBPs) control RNA metabolism to orchestrate gene expression, and dysfunctional RBPs underlie many human diseases. Proteome-wide discovery efforts predict thousands of novel RBPs, many of which lack canonical RNA-binding domains. Here, we present a hybrid ensemble RBP classifier...

Full description

Saved in:
Bibliographic Details
Published inbioRxiv
Main Authors Jin, Wenhao, Brannan, Kristopher W, Kapeli, Katannya, Park, Samuel S, Tan, Hui Qing, Gosztyla, Maya L, Mujumdar, Mayuresh, Ahdout, Joshua, Henroid, Bryce, Rothamel, Katherine, Xiang, Joy S, Wong, Limsoon, Yeo, Gene W
Format Paper
LanguageEnglish
Published Cold Spring Harbor Cold Spring Harbor Laboratory Press 24.12.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:RNA-binding proteins (RBPs) control RNA metabolism to orchestrate gene expression, and dysfunctional RBPs underlie many human diseases. Proteome-wide discovery efforts predict thousands of novel RBPs, many of which lack canonical RNA-binding domains. Here, we present a hybrid ensemble RBP classifier (HydRA) that leverages information from both intermolecular protein interactions and internal protein sequence patterns to predict RNA-binding capacity with unparalleled specificity and sensitivity using support vector machine, convolutional neural networks and transformer-based protein language models. HydRA enables Occlusion Mapping to robustly detect known RNA-binding domains and to predict hundreds of uncharacterized RNA-binding domains. Enhanced CLIP validation for a diverse collection of RBP candidates reveals genome-wide targets and confirms RNA-binding activity for HydRA-predicted domains. The HydRA computational framework accelerates construction of a comprehensive RBP catalogue and expands the set of known RNA-binding protein domains.Competing Interest StatementG.W.Y. is a co-founder, member of the Board of Directors, on the SAB, equity holder, and paid consultant for Locanabio and Eclipse BioInnovations. G.W.Y. is a visiting professor at the National University of Singapore. G.W.Y.'s interests have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. The authors declare no other competing financial interests.Footnotes* We added a new affiliation for co-author Kristopher W. Brannan in the author list and the manuscript file.
DOI:10.1101/2022.12.23.521837